Leukotriene B<sub>4</sub> licenses inflammasome activation to enhance skin host defense.

Salina, Ana Carolina Guerta; Brandt, Stephanie L; Klopfenstein, Nathan; Blackman, Amondrea; Bazzano, Júlia Miranda Ribeiro; Sá-Nunes, Anderson; Byers-Glosson, Nicole; Brodskyn, Claudia et al. · Proc Natl Acad Sci U S A · 2020

basic_science · Level V

Where this comes from

Abstract

The initial production of inflammatory mediators dictates host defense as well as tissue injury. Inflammasome activation is a constituent of the inflammatory response by recognizing pathogen and host-derived products and eliciting the production of IL-1β and IL-18 in addition to inducing a type of inflammatory cell death termed "pyroptosis." Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) is a lipid mediator produced quickly (seconds to minutes) by phagocytes and induces chemotaxis, increases cytokine/chemokine production, and enhances antimicrobial effector functions. Whether LTB<sub>4</sub> directly activates the inflammasome remains to be determined. Our data show that endogenously produced LTB<sub>4</sub> is required for the expression of pro-IL-1β and enhances inflammasome assembly in vivo and in vitro. Furthermore, LTB<sub>4</sub>-mediated Bruton's tyrosine kinase (BTK) activation is required for inflammasome assembly in vivo as well for IL-1β-enhanced skin host defense. Together, these data unveil a new role for LTB<sub>4</sub> in enhancing the expression and assembly of inflammasome components and suggest that while blocking LTB<sub>4</sub> actions could be a promising therapeutic strategy to prevent inflammasome-mediated diseases, exogenous LTB<sub>4</sub> can be used as an adjuvant to boost inflammasome-dependent host defense.

Medical subject headings